vorinostat has been researched along with Myeloproliferative Disorders in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When vorinostat was combined with antioxidant agents, the apoptosis of MPN cells increased in a synergistic manner." | 1.51 | Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms. ( Almeida, AM; Belo, H; Cardoso, BA; Ramos, TL; Real, C; Vilas-Boas, F, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cardoso, BA | 2 |
| Ramos, TL | 1 |
| Belo, H | 2 |
| Vilas-Boas, F | 1 |
| Real, C | 1 |
| Almeida, AM | 2 |
| Hao, X | 1 |
| Xing, W | 1 |
| Yuan, J | 1 |
| Wang, Y | 1 |
| Bai, J | 2 |
| Zhou, Y | 1 |
| Barata, JT | 1 |
3 other studies available for vorinostat and Myeloproliferative Disorders
| Article | Year |
|---|---|
Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms.
Topics: Adult; Aged; Antioxidants; Apoptosis; Cell Line, Tumor; Drug Synergism; Female; Hematologic Neoplasm | 2019 |
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Drug Synergism; Histone Deacetylases | 2020 |
The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Female; Fusio | 2015 |